Managers / Q1 2024 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $133M in U.S.-listed holdings across 10 positions for Q1 2024.
Its largest position, ARWR, represents 19.5% of the portfolio.
Compared with Q4 2023, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 77.2% · $103M
- Other · 13.5% · $18M
- ADR · 9.3% · $12M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DTILPRECISION BIOSCIENCES INC | NEW | +385.4K | 385.4K | +$5M | $5M |
| SUTRO BIOPHARMA INC | ADDED | +744.8K | 1.17M | +$5M | $7M |
| XBIS&P BIOTECH ETF TR | SOLD OUT | −200.0K | 0 | −$18M | $0 |
| KYMRKYMERA THERAPEUTICS INC | TRIMMED | −492.6K | 388.7K | −$7M | $16M |
| SLNSILENCE THERAPEUTICS PLC | TRIMMED | −469.1K | 574.2K | −$6M | $12M |
| BLUEPRINT MEDICINES CORP | TRIMMED | −72.7K | 182.2K | −$6M | $17M |
| MERUS N V | TRIMMED | −100.0K | 255.1K | +$2M | $11M |
| ARVNARVINAS INC | TRIMMED | −83.4K | 405.8K | −$3M | $17M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 19.47% | $26M | 908.5K |
| 2 | RGNXREGENXBIO INChistory → | COM | 14.31% | $19M | 906.2K |
| 3 | BLUEPRINT MEDICINES CORP | COM | 12.95% | $17M | 182.2K |
| 4 | ARVNARVINAS INChistory → | COM | 12.55% | $17M | 405.8K |
| 5 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 11.71% | $16M | 388.7K |
| 6 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 9.30% | $12M | 574.2K |
| 7 | MERUS N V | COM | 8.61% | $11M | 255.1K |
| 8 | SUTRO BIOPHARMA INC | COM | 4.94% | $7M | 1.17M |
| 9 | DTILPRECISION BIOSCIENCES INChistory → | COM NEW | 3.92% | $5M | 385.4K |
| 10 | RPTXREPARE THERAPEUTICS INChistory → | COM | 2.24% | $3M | 633.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.